Iopromide (Ultravist, BAY86-4877)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diagnostic Imaging
Conditions
Diagnostic Imaging
Trial Timeline
Sep 1, 2011 → Nov 1, 2013
NCT ID
NCT01415414About Iopromide (Ultravist, BAY86-4877)
Iopromide (Ultravist, BAY86-4877) is a pre-clinical stage product being developed by Bayer for Diagnostic Imaging. The current trial status is completed. This product is registered under clinical trial identifier NCT01415414. Target conditions include Diagnostic Imaging.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03622801 | Pre-clinical | Completed |
| NCT02840903 | Pre-clinical | Completed |
| NCT01415414 | Pre-clinical | Completed |
| NCT01206257 | Pre-clinical | Completed |
Competing Products
11 competing products in Diagnostic Imaging
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Intralipid + ICI35,868 (Diprivan) + ICI35,868 (Diprivan) + EES0000645/A (SDS) | Johnson & Johnson | Phase 3 | 77 |
| Remimazolam Tosilate for Injection + Remimazolam Tosilate for Injection | Jiangsu Hengrui Medicine | Approved | 85 |
| BAY86-4367 + BAY86-4367 | Bayer | Phase 1 | 30 |
| F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) + F-18 DPA-714 (BAY85-8102) | Bayer | Phase 1 | 30 |
| Ultravist (Iopromide, BAY86-4877) | Bayer | Pre-clinical | 20 |
| Gadopentetate dimeglumine (Magnevist, BAY86-4882) | Bayer | Pre-clinical | 20 |
| Gadoxetic Acid Disodium (Primovist, BAY86-4873) | Bayer | Pre-clinical | 20 |
| Gadobutrol (Gadavist, Gadovist, BAY86-4875) + Gadoteridol (ProHance) | Bayer | Phase 3 | 74 |
| Xenetix + Visipaque | Guerbet | Approved | 77 |
| Iobitridol | Guerbet | Approved | 77 |
| Dotarem (gadoterate meglumine) + Magnevist (gadopentetate dimeglumine) | Guerbet | Phase 3 | 69 |